CyGenics takes 51% equity in an Australian cord blood banking business
CyGenics Ltd announced that it has taken a 51% controlling equity interest in BioCell Pty Ltd, an Australian cord blood stem cell banking business. BioCell commenced operations in August 2004 and is now the second largest cord blood banking business in Australia. The company has grown rapidly from its Melbourne base and now has operations nationally, with representatives in each state. BioCell has strategic relationships with the Sydney Adventist Hospital which provides Therapeutic Goods Administration (TGA) approved laboratory services in Sydney, and world class biotechnology logistic service provider, World Courier.
This acquisition will allow CyGenics to migrate its successful business model to the Australian market, thereby strengthening the regional position of the company and supporting future revenue growth.
CyGenics will have majority board representation following its acquisition of 51% of BioCell, effected through a cash injection of $530,000. All funds will be retained by BioCell and will be used as working capital to accelerate growth in market awareness and revenue.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.